Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer

BMC Cancer

Table 5 Multivariate analysis of overall survival

	p-value	Hazard Ratio	95%-Confidence Interval
RAS p21 Elevated vs. non elevated	0.003	2.927	1.43–5.99
CTC counts ≥5 vs. < 5 CTCs / 7.5 ml blood	< 0.001	3.775	2.01–7.10
Therapy line > 1st line vs. 1st line	0.002	2.817	1.48–5.37
Grading G3 vs. G1/2	0.026	1.380	1.04–1.83
Serum HER2 Elevated vs. non elevated	0.156	1.564	0.84–2.90
Menopausal status Post- vs. Premenopausal	0.298	0.732	0.41–1.32
ER status Positive vs. Negative	0.067	0.478	0.22–1.05
PR status Positive vs. Negative	0.486	1.297	0.62–2.70
HER2 status Positive vs. Negative	0.121	0.623	0.34–1.13
Number of metastatic sites Multiple vs. Single site	0.521	1.262	0.62–2.57
Metastatic spread Visceral (+/−) vs. bone only	0.567	1.566	0.33–7.54
CAIX Elevated vs. non elevated	0.300	1.381	0.75–2.54
TIMP1 Elevated vs. non elevated	0.066	1.741	0.96–3.15

ISSN: 1471-2407